In 2022, a Phase I/II clinical trial using AAVrh74 to deliver GALGT2 cDNA driven by a MCK promoter was performed in two ambulant DMD patients at 6.9 and 8.9 years old at 1 × 1014 vg/kg and 5 × 1013 vg/kg total dose (Table 1) [54]. This evidence concerns the gene B4GALNT2 and Duchenne muscular dystrophy.